Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Exelixis focuses on active molecules generating differentiating clinical data in the GU/GI space, agnostic to modality and deal size. The company leads in synthetic lethality assets with XL-309 and XL-495. Recent sales growth in cabo attributed to strong demand, particularly in RCC.